ure is that they may benefit, not only from improved survival, but also from preventing or slowing the progression of further renal damage. Six patients with multiple myeloma and chronic renal insufficiency (serum creatinine Ͼ3.0 mg/dl), including
three patients on dialysis or 300 mg/m 2 /day for 2 days for 10 and 28 months after transplantation. These engraftment characteristics are comparable to patients with normal renal the remaining three patients). These doses represent a 50% reduction in cyclophosphamide and a 0-50% reduction in function receiving the same stem cell mobilization regimen and the same protocol of high-dose chemotherapy as preetoposide compared to those given to patients with normal renal function. All patients received G-CSF at a dose of 5 viously reported. 10 The median number of packed red cells transfused was 10 units (range 4-14 units). g/kg per day after the priming chemotherapy. Peripheral stem cells were collected over 4 days of apheresis as previously reported.
10
Toxicities High-dose chemotherapy consisted of busulfan and cyclophosphamide (BUCY), 10 with no dose adjustments for Chemotherapy was well tolerated. All patients had febrile renal failure. Busulfan was given by mouth at 1 mg/kg, neutropenia. There was one episode of documented bacevery 6 h for 16 doses. Cyclophosphamide was given intraterial sepsis, another patient had toxin-positive Clostridium venously at 60 mg/kg/day for 2 days. Empirically, stem difficile colitis. All of them received broad-spectrum anticells were infused 24 h after completion of high-dose therbiotics including aminoglycosides and amphotericin B, apy, but were delayed for an additional 24 h in patients on with dose adjustments made for renal function. Four hemodialysis (n = 3). Patients requiring renal replacement patients developed grade III and two, grade II mucositis. therapy were dialyzed prior to the first dose of cyclophosThere were no significant cardiopulmonary complications. phamide and then at 24 and 48 h, after completion of the Renal function remained stable throughout the hospital second dose. Otherwise, their hemodialysis schedule was course. The median number of days of hospitalization was unchanged, at three times a week throughout the transplant 26 (range 23-39 days). There was one toxicity-related period. All patients received G-CSF (5 g/kg/day) after death. One patient developed a spontaneous, massive sub-PBSCT until the absolute neutrophil count (ANC) was dural hematoma on day 11, and expired the following day greater than 1.0 × 10 9 /l for 3 consecutive days. Tumor from complications. Her platelet count was 14 × 10 9 /l at the responses were assessed by restaging procedures done at 3 time of the first neurological signs. and 6 months after transplant.
Response and survival

Results
Two patients achieved and have remained in CR, 28 and 39 months after transplantation. Three achieved PR, one of Stem cell collection whom relapsed at 5 months post-transplant with hypercalcemia and expired. The other two patients remain in PR, 6 The yield of total peripheral blood nucleated cells, CD34 + and 10 months post-transplant. The patient who died during cells and CFU-GM cells collected from patients with myethe acute transplant period had no evidence of active myeloma and renal failure were not significantly different from loma at autopsy. Overall survival of patients with renal failthose observed in a group of 20 consecutive patients with ure was not significantly different when compared to those myeloma and normal renal function transplanted during the with normal renal function (Kaplan-Meier estimates, log same period of time with an identical regimen (Table 1) . rank test P = 0.82).
Engraftment
Renal function Neutrophil recovery was rapid in all patients. The median number of days to an ANC of more than 0.5 × 10 9 /l was The three patients on hemodialysis at the time of transplant included the patient who died during the transplantation 11 days (range 9-15 days). This pattern of engraftment was not significantly different from that of myeloma patients period, as described above. The second one is alive (in PR at 10 months) and still requires hemodialysis. The last with normal renal function. However, platelet recovery (self-sustained platelet count Ͼ20 × 10 9 /l) was delayed in patient is still alive in CR at 28 months, and has shown a progressive recovery of renal function. Her serum creatintwo patients. They are still platelet transfusion-dependent, ine has decreased from a pre-transplant value of 7.7 to 4.0 even improvement of renal function. We conclude that patients with multiple myeloma and renal insufficiency mg/dl and she requires only intermittent hemodialysis.
should not be excluded from protocols for high-dose therapy. The role of PBSCT in this subgroup of patients should be further defined. Discussion Renal failure is a common complication in myeloma, References increasing in frequency and severity with advanced disease. indicator. Improved survival has been reported for patients
